Renal Cell Carcinoma

More than 1200 individuals die from renal cell carcinoma on an annual basis in the US. During the 1990s a significant amount of the new information concerning the epidemiology, molecular and immunologic characteristics and therapy for patients with these tumours has appeared. In this text, Drs Bukowski and Novick and a core of expert clinicians highlight these advances thus enabling urologists, medical oncologists and radiation oncologists in their treatment of patients with renal cell carcinoma. They further explore novel therapeutic aspects including the use of interferon, Interlukin-2 therapy for metastatic renal cell carcinoma, monoclonal antibody therapies, and antigeniogenic treatments to name a few.